VolitionRx Limited announced that it will commence a large internal clinical study for its Nucleosomics(R) diagnostic products in January 2013. This trial is being undertaken in addition to its four ongoing external clinical trials. The trial will be carried out in Volition's laboratory on patient blood samples supplied by the Wales Cancer Bank.

Beginning late January, NuQ(R) tests will be conducted on blood samples taken from more than 800 cancer patients by the Wales Cancer Bank as well as healthy control volunteers. The expected sample distribution is as follows: Breast cancer: approx. 550 patients with a variety of subtypes, including invasive ductal carcinoma, invasive lobular and tubular carcinomas, and in-situ carcinoma ductal; Colorectal cancer: approx.

230 patients with a variety of subtypes, at various stages from Stage A to Stage D; Plus smaller numbers of patients with lung and pancreatic cancers.